End Organ Affection in Sickle Cell Disease.

Area of Science:

• Hematology
• Genetics
• Rare Diseases

Background:

• Sickle cell disease (SCD) is a significant orphan disease disproportionately affecting ethnic minorities.
• It is a single-gene disorder characterized by red blood cell sickling and hemoglobin deoxygenation, leading to hemolysis and systemic complications.
• SCD affects approximately 100,000 individuals in the US, with its exact prevalence unknown.

Purpose of the Study:

• To provide a comprehensive overview of sickle cell disease's clinical manifestations and pathogenesis.
• To focus on end-organ damage associated with SCD.
• To review current and emerging therapeutic options, including recent FDA-approved treatments.

Main Methods:

• Literature review of clinical manifestations and pathogenesis of SCD.
• Analysis of acute and chronic complications, with emphasis on end-organ damage.
• Survey of existing and novel therapeutic strategies, including gene and stem cell therapies.

Main Results:

• SCD presents with acute crises (e.g., vaso-occlusive events, infections) and chronic target organ damage (e.g., pulmonary and renal failure).
• Genetic therapies offer potential to modify the disease's fundamental process.
• Mitigating or reversing end-organ damage remains a primary challenge in SCD management.

Conclusions:

• Understanding SCD pathogenesis and clinical course is crucial for effective management.
• Recent advancements in stem cell and gene editing therapies show promise for treating SCD.
• Addressing end-organ damage is a critical area for future therapeutic development in sickle cell disease.